• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pieris Pharmaceuticals, Inc. - Common Stock (NQ:PIRS)

13.60 UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 13.60
Bid (Size) 9.050 (1)
Ask (Size) 15.00 (2)
Prev. Close 13.60
Today's Range 13.60 - 13.60
52wk Range 13.60 - 18.68
Shares Outstanding 98,935,025
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS
November 20, 2024
From Kahn Swick & Foti, LLC
Via Business Wire
Palvella Therapeutics Announces First Patient Dosed in SELVA Phase 3 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations
November 07, 2024
From Palvella Therapeutics
Via GlobeNewswire

Performance

YTD
N/A
N/A
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
N/A
N/A
1 Year
-16.8%
-16.8%

More News

Read More
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer
October 17, 2024
From Palvella Therapeutics
Via GlobeNewswire
Looking Into Pieris Pharmaceuticals's Recent Short Interest
May 09, 2024
Via Benzinga
PIRS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pieris Pharmaceuticals, Inc. Is Fair to Shareholders
September 03, 2024
From Halper Sadeh LLC
Via Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AFBI, ENV, PIRS, BALY on Behalf of Shareholders
August 17, 2024
From Halper Sadeh LLC
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K and PIRS on Behalf of Shareholders
August 16, 2024
From Halper Sadeh LLC
Via GlobeNewswire
PIRS Stock Earnings: Pieris Pharmaceuticals Reported Results for Q2 2024
August 15, 2024
Via InvestorPlace
PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS
July 24, 2024
From Kahn Swick & Foti, LLC
Via Business Wire
Crude Oil Gains 1%; AT&T Shares Rise After Q2 Earnings
July 24, 2024
Via Benzinga
ALLR Stock Alert: Allarity Therapeutics Pushes Shareholders to Back Reverse Split
July 24, 2024
Via InvestorPlace
Dow Tumbles 300 Points; Tesla Shares Plunge After Q2 Results
July 24, 2024
Via Benzinga
Topics Stocks
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
July 24, 2024
Via Benzinga
Why Is Pieris Pharmaceuticals (PIRS) Stock Up 77% Today?
July 24, 2024
Via InvestorPlace
PIRS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pieris Pharmaceuticals, Inc. Is Fair to Shareholders
July 24, 2024
From Halper Sadeh LLC
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
July 24, 2024
Via InvestorPlace
Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement
July 24, 2024
Via ACCESSWIRE
PIRS Stock Earnings: Pieris Pharmaceuticals Reported Results for Q1 2024
May 17, 2024
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
May 16, 2024
Via Benzinga
Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split
April 19, 2024
Via ACCESSWIRE
Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential
March 27, 2024
Via ACCESSWIRE
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
March 20, 2024
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
March 14, 2024
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
January 31, 2024
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
December 13, 2023
Via Benzinga

Frequently Asked Questions

Is Pieris Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Pieris Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Pieris Pharmaceuticals, Inc. - Common Stock trade on?
Pieris Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Pieris Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Pieris Pharmaceuticals, Inc. - Common Stock is PIRS on the Nasdaq Stock Market
What is the current price of Pieris Pharmaceuticals, Inc. - Common Stock?
The current price of Pieris Pharmaceuticals, Inc. - Common Stock is 13.60
When was Pieris Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Pieris Pharmaceuticals, Inc. - Common Stock was at 12/13/24 04:00 PM ET
What is the market capitalization of Pieris Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Pieris Pharmaceuticals, Inc. - Common Stock is 1.35B
How many shares of Pieris Pharmaceuticals, Inc. - Common Stock are outstanding?
Pieris Pharmaceuticals, Inc. - Common Stock has 1B shares outstanding.
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap